FAIRFIELD, N.J., Jan. 23, 2012 /PRNewswire/ -- Aperture Health, Inc. (OTC: APRE) announced that it has achieved full OTC Pink status with its public disclosure and reporting of interim financial data in conjunction with current required disclosure documentation for OTC PINK listing compliance.

Aperture Health, Inc., a Nevada Corporation, through the Company's wholly owned subsidiary, Triad Therapeutics, Inc., provides specialized home healthcare services to patient clients requiring intravenous therapy including antibiotics, pain management, total nutritional support, hydration, steroids, immunoglobulins and IV catheter insertions and maintenance. The Company provides a complete solution to patients including the preparation and delivery of sterile compounded IV medications, supplies and equipment, along with specialized nursing care and teaching of the patient and/or caregivers on the administration of therapies as prescribed by a physician.

James Hennig, R.Ph, Chief Executive Officer and Chairman of the Board of Directors commented, "We are very pleased to qualify and be designated "OTC PINK Current Information" based upon our commitment and efforts to provide the investing public with as much relevant financial and disclosure information about Aperture Health and its' business."

Safe Harbor

Certain statements in this news release are forward-looking, including (without limitation) growing revenues and earnings, expected results from current projects and attracting new business.  Undue reliance should not be placed on such forward-looking statements because the matters they describe are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company's control. The Company's actual results, performance and trends could differ materially from those indicated or implied by such statements as a result of various factors, including (without limitation) the continued strengthening of Triad's selling and marketing functions, continued customer satisfaction, contract renewal, new product development, continued availability of capable dedicated personnel, continued cost management, success and availability of acquisitions, availability of financing and other factors, as well as by factors applicable to most companies such as general economic, competitive and other business and civil conditions.  Information regarding certain of those and other risk factors and cautionary statements that could affect future results, performance or trends is discussed in the Company's OTC Disclosure Statement and unaudited management financials posted on www.pinksheets.com .  All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.  The information set forth herein speaks only as of the date hereof.

 

 

SOURCE Aperture Health, Inc.

Copyright 2012 PR Newswire

Elinx (CE) (USOTC:ELNX)
過去 株価チャート
から 12 2024 まで 1 2025 Elinx (CE)のチャートをもっと見るにはこちらをクリック
Elinx (CE) (USOTC:ELNX)
過去 株価チャート
から 1 2024 まで 1 2025 Elinx (CE)のチャートをもっと見るにはこちらをクリック